Zylox-Tonbridge Buys Back 28,500 H Shares for HK$0.67 Million; Treasury Stock Tops 7.13 Million

Bulletin Express03-24 20:02

Zylox-Tonbridge Medical Technology Co., Ltd. disclosed that on 24 March 2026 it repurchased 28,500 H shares on the Hong Kong Stock Exchange at prices ranging from HK$22.86 to HK$23.50, spending a total of HK$0.67 million.

Following the transaction, the company’s issued shares (excluding treasury shares) decreased to 329.23 million, while treasury shares rose to 7.13 million. Total outstanding shares remained unchanged at 336.35 million. The latest buy-back equates to 0.0085 % of the company’s issued share capital prior to the repurchase.

The repurchase forms part of a mandate approved on 30 May 2025 that authorises the company to buy back up to 31.96 million shares. Including the latest transaction, Zylox-Tonbridge has repurchased 4.31 million shares under this mandate, representing 1.32 % of the share count at the mandate date.

In line with Hong Kong listing rules, a moratorium on new share issues or sales of treasury shares is in effect until 23 April 2026. The company confirmed that the repurchase complied with all applicable regulations and that all required funds have been fully settled.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151574000?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151574000","market":"hk","top_or_hot":-1,"title":"Zylox-Tonbridge Buys Back 28,500 H Shares for HK$0.67 Million; Treasury Stock Tops 7.13 Million","media":"Bulletin Express","content":"<p>Zylox-Tonbridge Medical Technology Co., Ltd. disclosed that on 24 March 2026 it repurchased 28,500 H shares on the Hong Kong Stock Exchange at prices ranging from HK$22.86 to HK$23.50, spending a total of HK$0.67 million.</p>\n<p>Following the transaction, the company’s issued shares (excluding treasury shares) decreased to 329.23 million, while treasury shares rose to 7.13 million. Total outstanding shares remained unchanged at 336.35 million. The latest buy-back equates to 0.0085 % of the company’s issued share capital prior to the repurchase.</p>\n<p>The repurchase forms part of a mandate approved on 30 May 2025 that authorises the company to buy back up to 31.96 million shares. Including the latest transaction, Zylox-Tonbridge has repurchased 4.31 million shares under this mandate, representing 1.32 % of the share count at the mandate date.</p>\n<p>In line with Hong Kong listing rules, a moratorium on new share issues or sales of treasury shares is in effect until 23 April 2026. The company confirmed that the repurchase complied with all applicable regulations and that all required funds have been fully settled.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zylox-Tonbridge Buys Back 28,500 H Shares for HK$0.67 Million; Treasury Stock Tops 7.13 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZylox-Tonbridge Buys Back 28,500 H Shares for HK$0.67 Million; Treasury Stock Tops 7.13 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-24 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zylox-Tonbridge Medical Technology Co., Ltd. disclosed that on 24 March 2026 it repurchased 28,500 H shares on the Hong Kong Stock Exchange at prices ranging from HK$22.86 to HK$23.50, spending a total of HK$0.67 million.</p>\n<p>Following the transaction, the company’s issued shares (excluding treasury shares) decreased to 329.23 million, while treasury shares rose to 7.13 million. Total outstanding shares remained unchanged at 336.35 million. The latest buy-back equates to 0.0085 % of the company’s issued share capital prior to the repurchase.</p>\n<p>The repurchase forms part of a mandate approved on 30 May 2025 that authorises the company to buy back up to 31.96 million shares. Including the latest transaction, Zylox-Tonbridge has repurchased 4.31 million shares under this mandate, representing 1.32 % of the share count at the mandate date.</p>\n<p>In line with Hong Kong listing rules, a moratorium on new share issues or sales of treasury shares is in effect until 23 April 2026. The company confirmed that the repurchase complied with all applicable regulations and that all required funds have been fully settled.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02190","symbol_name":"归创通桥","start_time":0,"source_url":"","article_id":"1151574000","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151574000","pubTimestamp":1774353752,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Zylox-Tonbridge Medical Technology Co., Ltd. disclosed that on 24 March 2026 it repurchased 28,500 H shares on the Hong Kong Stock Exchange at prices ranging from HK$22.86 to HK$23.50, spending a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02190":"归创通桥"},"translate_title":"Zylox-Tonbridge以67万港元回购2.85万股H股；库存股突破713万","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02190":1},"content_text":"Zylox-Tonbridge Medical Technology Co., Ltd. disclosed that on 24 March 2026 it repurchased 28,500 H shares on the Hong Kong Stock Exchange at prices ranging from HK$22.86 to HK$23.50, spending a total of HK$0.67 million.\nFollowing the transaction, the company’s issued shares (excluding treasury shares) decreased to 329.23 million, while treasury shares rose to 7.13 million. Total outstanding shares remained unchanged at 336.35 million. The latest buy-back equates to 0.0085 % of the company’s issued share capital prior to the repurchase.\nThe repurchase forms part of a mandate approved on 30 May 2025 that authorises the company to buy back up to 31.96 million shares. Including the latest transaction, Zylox-Tonbridge has repurchased 4.31 million shares under this mandate, representing 1.32 % of the share count at the mandate date.\nIn line with Hong Kong listing rules, a moratorium on new share issues or sales of treasury shares is in effect until 23 April 2026. The company confirmed that the repurchase complied with all applicable regulations and that all required funds have been fully settled.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151574000","isCrawlerRequest":true}